Core Viewpoint - Baiaosaitu (Beijing) Pharmaceutical Technology Co., Ltd. has successfully listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board, with a significant opening price increase of 146.63% on its first trading day, indicating strong market interest and investor confidence in the company [1]. Group 1: Company Overview - Baiaosaitu is a preclinical CRO and biotechnology company, with major shareholders including Shen Yulei and Ni Jian, who collectively control 26.87% of the voting rights [1]. - The company has a total market capitalization of 25.073 billion yuan at the close of its first trading day [1]. Group 2: Financial Performance - The company reported revenues of 53.39 million yuan, 71.69 million yuan, and 98.05 million yuan for the years 2022 to 2024, respectively, with a net profit of -60.22 million yuan, -38.30 million yuan, and 3.35 million yuan during the same period [5]. - For the first nine months of 2025, Baiaosaitu achieved a revenue of 94.09 million yuan, a year-on-year increase of 59.50%, and a net profit of 11.41 million yuan [6]. Group 3: Fundraising and Investment Plans - The company plans to raise a total of 1.2673 billion yuan through its public offering, with net proceeds of approximately 1.1441 billion yuan after deducting issuance costs [3]. - The funds will be allocated to various projects, including 38.28% for early drug research and development services, 26.70% for antibody drug research and evaluation, 13.92% for preclinical research projects, and 21.10% for working capital [4]. Group 4: Future Projections - For the fiscal year 2025, the company anticipates revenues of approximately 135.06 million yuan, representing a year-on-year growth of 37.75%, and a net profit of about 13.54 million yuan, reflecting a significant increase of 303.57% compared to the previous year [9].
百奥赛图上市募12.7亿首日涨147% 累计未弥补亏损17亿